Advertisement

MCL1 regulates cell death, tumor growth and chemosensitivity to sabutoclax in ovarian adenocarcinoma

  • Cui LiEmail author
  • Yuchun Song
  • Pan Li
Regular Article

Abstract

This research was conducted to study the role of MCL1 in ovarian adenocarcinoma cell death and survival as well as chemosensitivity to sabutoclax. Both in vitro and in vivo assays including qRT-PCR, Western blot, CCK-8, caspase 3/7 activation, colony foci formation assay and xenograft assay were conducted. Except for the xenograft assay, the other experiments were conducted at the cellular level and they were carried out to assess cell activities such as viability, programmed death and proliferation. SKOV3 and OVCAR3 cell lines were used as the cell models for all experiments. It was proved that MCL1 was overexpressed in ovarian adenocarcinoma (tissues and cells) at RNA and protein levels. MCL1 knockdown was also discovered to suppress the viability and proliferation of ovarian adenocarcinoma cells in vivo and in vitro. Lastly, it was found that MCL1 knockdown significantly promoted ovarian carcinoma cell death and the sensitivity to sabutoclax. Thus, we concluded that MCL1 acted as a cancer facilitator in ovarian adenocarcinoma and it is also a suppressor of sabutoclax sensitivity.

Keywords

MCL1 Tumor growth Sabutoclax Ovarian adenocarcinoma 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The ethics committee of the Yantai Affiliated Hospital, Binzhou Medical College, approved this research.

References

  1. Allen TD, Zhu CQ, Jones KD, Yanagawa N, Tsao MS, Bishop JM (2011) Interaction between MYC and MCL1 in the genesis and outcome of non-small-cell lung cancer. Cancer Res 71:2212–2221CrossRefGoogle Scholar
  2. Arnold JM, Huggard PR, Cummings M, Ramm GA, Chenevix-Trench G (2005) Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma. Br J Cancer 92:2024–2031CrossRefGoogle Scholar
  3. Bonnefond ML, Lambert B, Giffard F, Abeilard E, Brotin E, Louis MH, Gueye MS, Gauduchon P, Poulain L, N'Diaye M (2015) Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-xL strategies through Mcl-1 down-regulation. Apoptosis 20:535–550CrossRefGoogle Scholar
  4. Campbell KJ, Dhayade S, Ferrari N, Sims AH, Johnson E, Mason SM, Dickson A, Ryan KM, Kalna G, Edwards J, Tait SWG, Blyth K (2018) MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death Dis 9:19CrossRefGoogle Scholar
  5. Correa DD, Root JC, Kryza-Lacombe M, Mehta M, Karimi S, Hensley ML, Relkin N (2017) Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: a pilot study. Brain Imaging Behav 11:1652–1663CrossRefGoogle Scholar
  6. Dai H, Meng XW, Kaufmann SH (2016) Mitochondrial apoptosis and BH3 mimetics. F1000Res 5:2804CrossRefGoogle Scholar
  7. Dash R, Azab B, Quinn BA, Shen X, Wang XY, Das SK, Rahmani M, Wei J, Hedvat M, Dent P, Dmitriev IP, Curiel DT, Grant S, Wu B, Stebbins JL, Pellecchia M, Reed JC, Sarkar D, Fisher PB (2011) Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc Natl Acad Sci U S A 108:8785–8790CrossRefGoogle Scholar
  8. Denoyelle C, Lambert B, Meryet-Figuiere M, Vigneron N, Brotin E, Lecerf C, Abeilard E, Giffard F, Louis MH, Gauduchon P, Juin P, Poulain L (2014) miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation. Cell Death Dis 5:e1445CrossRefGoogle Scholar
  9. Englert-Golon M, Burchardt B, Budny B, Debicki S, Majchrzycka B, Wrotkowska E, Jasinski P, Ziemnicka K, Slopien R, Ruchala M, Sajdak S (2017) Genomic markers of ovarian adenocarcinoma and its relevancy to the effectiveness of chemotherapy. Oncol Lett 14:3401–3414CrossRefGoogle Scholar
  10. Goncharenko-Khaider N, Matte I, Lane D, Rancourt C, Piche A (2012) Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis. Mol Cancer 11:84CrossRefGoogle Scholar
  11. Habata S, Iwasaki M, Sugio A, Suzuki M, Tamate M, Satohisa S, Tanaka R, Saito T (2016) BAG3-mediated Mcl-1 stabilization contributes to drug resistance via interaction with USP9X in ovarian cancer. Int J Oncol 49:402–410CrossRefGoogle Scholar
  12. Jackson RS II, Placzek W, Fernandez A, Ziaee S, Chu CY, Wei J, Stebbins J, Kitada S, Fritz G, Reed JC, Chung LW, Pellecchia M, Bhowmick NA (2012) Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer. Neoplasia 14:656–665CrossRefGoogle Scholar
  13. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (2014) Ovarian cancer. Lancet 384:1376–1388CrossRefGoogle Scholar
  14. Koshiyama M, Matsumura N, Konishi I (2017) Subtypes of ovarian cancer and ovarian cancer screening. Diagnostics (Basel) 7(1)CrossRefGoogle Scholar
  15. Maji S, Samal SK, Pattanaik L, Panda S, Quinn BA, Das SK, Sarkar D, Pellecchia M, Fisher PB, Dash R (2015) Mcl-1 is an important therapeutic target for oral squamous cell carcinomas. Oncotarget 6:16623–16637CrossRefGoogle Scholar
  16. Merino D, Whittle JR, Vaillant F, Serrano A, Gong JN, Giner G, Maragno AL, Chanrion M, Schneider E, Pal B, Li X, Dewson G, Grasel J, Liu K, Lalaoui N, Segal D, Herold MJ, Huang DCS, Smyth GK, Geneste O, Lessene G, Visvader JE, Lindeman GJ (2017) Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. Sci Transl Med 9(401)CrossRefGoogle Scholar
  17. Opydo-Chanek M, Gonzalo O, Marzo I (2017) Multifaceted anticancer activity of BH3 mimetics: current evidence and future prospects. Biochem Pharmacol 136:12–23CrossRefGoogle Scholar
  18. Polom K, Roviello G, Generali D, Marano L, Petrioli R, Marsili S, Caputo E, Marrelli D, Roviello F (2016) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer. Int J Hyperthermia 32:298–310CrossRefGoogle Scholar
  19. Sarkar S, Pradhan A, Das SK, Emdad L, Sarkar D, Pellecchia M, Fisher PB (2016) Novel therapy of prostate cancer employing a combination of viral-based immunotherapy and a small molecule BH3 mimetic. Oncoimmunology 5:e1078059CrossRefGoogle Scholar
  20. Shi T, Wang P, Xie C, Yin S, Shi D, Wei C, Tang W, Jiang R, Cheng X, Wei Q, Wang Q, Zang R (2017) BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer. Int J Cancer 140:2051–2059CrossRefGoogle Scholar
  21. Sugio A, Iwasaki M, Habata S, Mariya T, Suzuki M, Osogami H, Tamate M, Tanaka R, Saito T (2014) BAG3 upregulates Mcl-1 through downregulation of miR-29b to induce anticancer drug resistance in ovarian cancer. Gynecol Oncol 134:615–623CrossRefGoogle Scholar
  22. Thomas S, Quinn BA, Das SK, Dash R, Emdad L, Dasgupta S, Wang XY, Dent P, Reed JC, Pellecchia M, Sarkar D, Fisher PB (2013) Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets 17:61–75CrossRefGoogle Scholar
  23. Varadarajan S, Butterworth M, Wei J, Pellecchia M, Dinsdale D, Cohen GM (2013) Sabutoclax (BI97C1) and BI112D1, putative inhibitors of MCL-1, induce mitochondrial fragmentation either upstream of or independent of apoptosis. Neoplasia 15:568–578CrossRefGoogle Scholar
  24. Vershinin Z, Feldman M, Chen A, Levy D (2016) PAK4 methylation by SETD6 promotes the activation of the Wnt/beta-catenin pathway. J Biol Chem 291:6786–6795CrossRefGoogle Scholar
  25. Wang X, Chen Z, Li X, Jiang ZK, Zhao YQ, Ping FF (2017) Geraniin suppresses ovarian cancer growth through inhibition of NF-κB activation and downregulation of Mcl-1 expression. J Biochem Mol Toxicol 31(9)CrossRefGoogle Scholar
  26. Whicker ME, Lin ZP, Hanna R, Sartorelli AC, Ratner ES (2016) MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib. BMC Cancer 16:550CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Gynaecology and ObstetricsYantai Affiliated Hospital, Binzhou Medical CollegeYantaiChina

Personalised recommendations